Abstract:Abstract Objective Alzheimer's disease (AD) is a degenerative disease of central nervous system with unclear pathogenesis, accounting for 60% - 70% of dementia cases. It is necessary to study the pathogenesis and therapeutic prospect of AD. LncRNAs have been found to play an important role in the development of AD. This study aims to explore the role of differentially expressed lncRNAs in AD patients' serum in the pathogenesis of AD. Methods In this study, serum microarray analysis was performed in AD patients and healthy controls to establish lncRNAs and mRNA expression profiles. The biological processes and key pathways were identified by GO analysis and KEGG pathway analysis. A protein-protein interaction network was analyzed and constructed by using String database. SH-SY5Y cells were treated with Aβ 1-42 to establish AD cell model. The expression of RP11-59J16.2 and MCM2 was detected by qRT-PCR. The mRNA binding sites and target genes of RP11-59J16.2 were predicted by bioinformatics analysis. Dual luciferase reporter gene analysis verified the targeting effect of RP11-59J16.2 on MCM2. Inhibition of RP11-59J16.2 or overexpression of MCM2, CCK-8 and flow cytometry were used to detect cell viability and apoptosis and Western Blot was used to detect the expression of p-Tau. Results Differential expression of lncRNAs and mRNAs was screened by microarray data, and high expression of RP11-59J16.2 and low expression of MCM2 were detected in serum of AD patients. GO analysis and KEGG pathway analysis revealed that G 1 /S transition of mitotic cell cycle may be involved in the development of AD. The mRNA binding sites and target genes of RP11-59J16.2 were predicted by bioinformatics analysis. Dual luciferase reporter gene analysis, qRT-PCR and Western Blot were used to verify the targeted regulation of RP11-59J16.2 on MCM2. The expression of RP11-59J16.2 was increased and that of MCM2 was decreased in SH-SY5Y cells treated with Aβ1-42. CCK-8 assay and Annexin V FITC/PI apoptosis assay kit results showed that RP11-59J16.2 could reduce cell viability, aggravate apoptosis and increase Tau phosphorylation in AD cell model by inhibiting MCM2. Conclusion Through gene microarray and bioinformatics analysis, high differentially expressed lncRNAs RP11-59J16.2 and low expressed mRNA MCM2 in AD patients were screened. By using bioinformatics prediction and dual luciferase reporter gene analysis, it was confirmed that RP11-59J16.2 could target MCM2 regulation. SH-SY5Y cells were treated with Aβ1-42 to construct AD cell model. Overexpression or inhibition of RP11-59J16.2 or MCM2, we found that RP11-59J16.2 could promote neuronal apoptosis and increase Tau phosphorylation by regulating MCM2 in vitro. Thus, RP11-59J16.2 might be a potential target molecule for the prediction, diagnosis and treatment of AD.

Ribosomal Protein S23 Retroposition 1 (RPS23R1)

A Functional Mouse Retroposed Gene Rps23r1 Reduces Alzheimer's Β-Amyloid Levels and Tau Phosphorylation

RPS23RG1 reduces Aβ oligomer-induced synaptic and cognitive deficits

Rps23rg1 Reduces A Beta Oligomer-Induced Synaptic And Cognitive Deficits

The Rps23rg Gene Family Originated Through Retroposition of the Ribosomal Protein S23 Mrna and Encodes Proteins That Decrease Alzheimer'S Beta-Amyloid Level and Tau Phosphorylation

The Rps23r1 gene family regulates Alzheimer's beta-amyloid generation and tau phosphorylation

P2‐312: the Rps23r1 Gene Family Regulates Alzheimer's Beta‐amyloid Generation and Tau Phosphorylation

RPS23RG1 is Required for Synaptic Integrity and Rescues Alzheimer's Disease-Associated Cognitive Deficits.

RPS23RG1 modulates tau phosphorylation and axon outgrowth through regulating p35 proteasomal degradation

Phenazopyridine Promotes RPS23RG1/Rps23rg1 Transcription and Ameliorates Alzheimer-associated Phenotypes in Mice

LncRNA RP11-59J16.2 aggravates apoptosis and increases tau phosphorylation by targeting MCM2 in AD

Rpph1 Upregulates CDC42 Expression and Promotes Hippocampal Neuron Dendritic Spine Formation by Competing with Mir-330-5p.

Proteomic Analysis of Protein Expression Throughout Disease Progression in a Mouse Model of Alzheimer’s Disease

TRPML1 Participates in the Progression of Alzheimer's Disease by Regulating the PPARγ/AMPK/Mtor Signalling Pathway

LncRNA RP11-59J16.2 Aggravates Apoptosis and Increases Tau Phosphorylation via Inhibiting MCM2 On The AD SH-SY5Y Cell Model Induced By Aβ.

TRPML1 Participates in the Progression of Alzheimer’s Disease by Regulating the PPARγ/AMPK/Mtor Signalling Pathway

ADAM10- and γ-secretase-dependent cleavage of the transmembrane protein PTPRT attenuates neurodegeneration in the mouse model of Alzheimer's disease

Upregulation of RIN3 Induces Endosomal Dysfunction in Alzheimer’s Disease

Ginsenoside Rg1 Ameliorates Behavioral Abnormalities and Modulates the Hippocampal Proteomic Change in Triple Transgenic Mice of Alzheimer's Disease

P3‐437: RAB10 PHOSPHORYLATION IS A PROMINENT PATHOLOGICAL FEATURE IN ALZHEIMER'S DISEASE

RGS2 expression predicts amyloid-β sensitivity, MCI and Alzheimer's disease: genome-wide transcriptomic profiling and bioinformatics data mining